"development of a second generation polymyxin for therapy of MDR gram-negative infections"
Ended Definitive Contract Awarded Last action
- Contract number
- HHSN272201500014C
- Awardee
-
Spero Therapeutics, Inc. UEI NX34PL7NZW24
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $5,923,719
Award facts
- Opportunity
-
- NIHAI2014007 Solicitation number
- Targeting Therapeutics Development to Relieve Bottlenecks Award Notice · Posted Jun 13, 2014
- Request for Infomration (RFI) : Optimizing Lead Therapeutic Compounds Against Infectious Pathogens - Amendment 1 Award Notice · Posted Mar 21, 2014
- Contract value 63% obligated
-
- $5,923,718.98 Current, with exercised options
- $9,391,175.98 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 25 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Great Britain, United Kingdom
- Legislative mandates
-
- Clinger-Cohen Act FAR part 39
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$4,302 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Supplemental Agreement for work within scope | $210,895 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $295,790 | |
| Supplemental Agreement for work within scope | $275,342 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Novation Agreement | $0 | |
| Exercise an Option | $1,818,396 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $197,115 | |
| Change Order | $1,634,580 | |
| Other Administrative Action | $0 | |
| Original award | $1,495,903 |
Show all 20
About this award
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $9,391,175.98 cost-plus-fixed-fee contract to Spero Therapeutics, Inc. to develop a second-generation polymyxin for the treatment of multidrug-resistant (MDR) Gram-negative infections. The contract, which does not have a set-aside designation, has a period of performance through June 15, 2021. Spero Therapeutics, Inc. is a for-profit organization based in Cambridge, Massachusetts.
Quick answers
Who was awarded contract HHSN272201500014C?
HHSN272201500014C was awarded to Spero Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on June 30, 2015.
How much is contract HHSN272201500014C worth?
The government has obligated $5,923,719 on HHSN272201500014C. Its potential value, with all options, is $9,391,176.
Was contract HHSN272201500014C competed?
The extent of competition for HHSN272201500014C was full and open competition. The government received 25 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award